---
title: Adj Assoc Prof Chee Cheng Ean
permalink: /leaders/adj-assoc-prof-chee-cheng-ean/
description: ""
third_nav_title: Executive Committee
variant: tiptap
---
<p></p>
<h5></h5>
<div class="isomer-image-wrapper">
<img style="width: 40%;" height="auto" width="100%" alt="" src="/images/Leaders/EXCO 600x450/Chee_Cheng_Ean_3.jpg">
</div>
<h5>Affiliations</h5>
<p>Platform Lead,&nbsp;Impact &amp; Population Health, Singapore Translational
Cancer Consortium;</p>
<p>Executive Director, National University Cancer Institute, Singapore</p>
<p>Adjunct Associate Professor, Department of Medicine, Yong Loo Lin School
of Medicine, National University of Singapore</p>
<p>Senior Consultant, Department of Haematology-Oncology, National University
Cancer Institute, Singapore</p>
<h5>Profile</h5>
<p><strong>Adj A/Prof Chee Cheng Ean </strong>is the Executive Director of
the National University Cancer Institute, Singapore. In this role, she
provides leadership and direction, and is responsible for implementing
strategic initiatives for NCIS (pronounced N-CIS), which is the only public,
academic cancer center in Singapore treating both pediatric and adult cancers
in one facility. Adj A/Prof Chee is also a senior consultant, gastrointestinal
(GI) oncologist and clinician investigator. Her portfolio includes clinical
and research initiatives in precision oncology and clinical trials involving
novel therapeutics in GI cancers which have been awarded institutional
and national grant funding. She also leads the cancer survivorship programme
at NCIS and is a proponent of value-based healthcare initiatives.</p>
<p></p>
<p><strong>Selected Publications</strong>
</p>
<ul data-tight="true" class="tight">
<li>
<p>Loh J, Wu J, Chieng J, Chan A, Yong WP, Sundar R, Lee SC, Wong A, Lim
JSJ, Tan DSP, Soo R, Goh BC, Tai BC, Chee CE. Clinical outcome and prognostic
factors for Asian patients in Phase I clinical trials. Br J Cancer. 2023
Apr;128(8):1514-1520. doi: 10.1038/s41416-023-02193-2. Epub 2023 Feb 16.
PMID: 36797357; PMCID: PMC10070409.</p>
</li>
<li>
<p>Chee CE, Ooi M, Lee SC, Sundar R, Heong V, Yong WP, Ng CH, Wong A, Lim
JSJ, Tan DSP, Soo R, Tan JTC, Yang S, Thura M, Al-Aidaroos AQ, Chng WJ,
Zeng Q, Goh BC. A Phase I, First-in-Human Study of PRL3-zumab in Advanced,
Refractory Solid Tumors and Hematological Malignancies. Target Oncol. 2023
Apr 15. doi: 10.1007/s11523-023-00962-w. Epub ahead of print. PMID: 37060431.</p>
</li>
<li>
<p>Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan
P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD,
Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC,
Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation
for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary
Association consensus guidelines. Lancet Gastroenterol Hepatol. 2021 Sep
7. PMID: 34506756.</p>
</li>
<li>
<p>Sarker D, Plummer R, Meyer T, Sodergren M, Basu B, Chee CE, Huang KW,
et al. MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-Î±,
in patients with advanced liver cancer: a first-in-human, multi-centre,
open-label, phase I trial. Clin Cancer Res. 2020;26(15):3936-3946.</p>
</li>
<li>
<p>Chan GHJ, Chee CE. Perioperative Chemotherapy for Liver Metastasis of
Colorectal Cancer. Cancers. 2020;12(12):3535.</p>
</li>
<li>
<p>Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung
HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE,
Omori T, et al. Safety and Efficacy of Durvalumab and Tremelimumab Alone
or in Combination in Patients with Advanced Gastric and Gastroesophageal
Junction Adenocarcinoma. Clin Cancer Res. 2020;26(4):846-854.</p>
</li>
<li>
<p>Chan GHJ, Chee CE. Making sense of adjuvant chemotherapy in colorectal
cancer. J Gastrointest Oncol. 2019 Dec;10(6):1183-1192.</p>
</li>
<li>
<p>Sundar R, Tan IBH, Chee CE. Negative Predictive Biomarkers in Colorectal
Cancer: PRESSING Ahead. J Clin Oncol. 2019 Nov 20;37(33):3066-3068.</p>
</li>
<li>
<p>Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ 3rd,
Heit JA. Predictors of Venous Thromboembolism Recurrence and Bleeding Among
Active Cancer Patients: A Population-Based Cohort Study. Blood. 2014; 123(25):
3972-8.</p>
</li>
<li>
<p>Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, et al. PRL3-zumab as
an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun.
2019;10(1):2484.</p>
</li>
</ul>
<p></p>